| Revenue growth | FY26 revenue up 12.3% to ₹1,875cr; H2 outperformed H1 by 21%. |
|---|---|
| Margins | Gross margins expanded 128bps to 68%; Q4 consolidated EBITDA at 21%. |
| Demand visibility | Strong domestic and international demand; visibility improving in US and Europe. |
| Management confidence | Confident but cautious regarding global geopolitical volatility and raw material inflation. |
Growth
FY26 consolidated revenue rose 12.3% to ₹1,875cr; H2 grew 21% over H1, meeting prior H2 guidance.
Outlook
FY27 revenue guidance is ₹2,300-₹2,400cr (22-28% growth); EBITDA margins guided at 23-25%.
Risks
Raw material costs surged 20% due to crude prices; geopolitical disruptions in Red Sea impact logistics.
Earnings Call filed with BSE, NSE: POLYMED. Summary written with AI assistance from the document.
Poly Medicure Ltd: key numbers
- Share price
- ₹1,599.50
- Market cap
- ₹16,213 Cr
- Revenue (annual)
- ₹1,875 Cr
- Net profit (annual)
- ₹322.1 Cr
- P/E (TTM)
- 51.5×Sector 53.1×
- Promoter holding
- 62.42%+0.00% QoQ
- FII holding
- 5.56%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Poly Medicure Ltd
All →Poly Medicure Annual General Meeting
Poly Medicure conducted its 31st Annual General Meeting on September 5, 2026, via video conferencing. This filing provides a summary of the meeting's proceedings and agenda items.
Poly Medicure Annual Report
Poly Medicure has filed its Notice of the 31st Annual General Meeting and the Annual Report for the financial year ended March 31, 2026.
Poly Medicure Dividend
Poly Medicure has announced a record date of August 29, 2026, for a final dividend of ₹3.50 per equity share for FY 2025-26.
Poly Medicure Annual General Meeting
Poly Medicure Limited has scheduled its 31st Annual General Meeting for September 05, 2026, to transact ordinary and special businesses, including dividend declaration.
Poly Medicure Earnings Call Transcript: Key Takeaways
PolyMed Q1FY27 shows strong standalone margin performance beating guidance, but consolidated numbers are dragged by the Middle East crisis and pricing pressure in the renal segment from Chinese dumping.
- Call
- Guides 100% growth
Poly Medicure Employee Stock Options
Poly Medicure Limited allotted equity shares under its Employee Stock Option Plan (ESOP). This issuance increases the company's paid-up share capital.